EMAN SHARAWY: Open Payments
NPI 1902998032 · GREENWOOD, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,882 in 106 payments from 14 companies in 2025. Trend: 2023 $1,589 · 2024 $1,965 · 2025 $1,882
Food & beverage: $1,882
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 14 | $320 |
| Neurocrine BioSciences, Inc. | 14 | $252 |
| E.R. Squibb & Sons, L.L.C. | 8 | $237 |
| ABBVIE INC. | 20 | $205 |
| Janssen Pharmaceuticals, Inc | 11 | $184 |
| Teva Pharmaceuticals USA, Inc. | 12 | $139 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $120 |
| Alkermes, Inc. | 6 | $111 |
| Supernus Pharmaceuticals, Inc. | 5 | $91 |
| Collegium Pharmaceutical, Inc. | 3 | $56 |
Products named: COBENFY, INGREZZA, VRAYLAR, ABILIFY ASIMTUFII, INVEGA SUSTENNA, CAPLYTA, REXULTI, Qelbree.
Industry payments across SC — which companies pay providers there.
